Cardiac pacing in the long QT syndrome: review of available data and practical recommendations

S Viskin1

  • 1Department of Cardiology, Sourasky-Tel Aviv Medical Center, and Sackler-School of Medicine, Tel Aviv University, Israel. viskin_s@netvision.net.il

Insights

Cardiac pacing may prevent arrhythmic death in Long QT Syndrome (LQTS) patients, especially those with LQT3 or pause-dependent arrhythmias. Careful pacemaker programming is crucial to avoid pauses and optimize patient selection for this intervention.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Medical Devices

Background:

  • Long QT Syndrome (LQTS) is a condition associated with increased risk of life-threatening arrhythmias.
  • Cardiac pacing is a potential therapeutic strategy for managing LQTS.
  • Optimization of pacing strategies is needed to improve outcomes and prevent sudden cardiac death in LQTS patients.

Purpose of the Study:

  • To review existing data on cardiac pacing in Long QT Syndrome (LQTS).
  • To identify patient selection criteria and pacemaker programming parameters that may prevent arrhythmic death.
  • To evaluate the potential benefits of pacing across different LQTS genotypes.

Main Methods:

  • Systematic review of published literature on cardiac pacing in LQTS.
  • Analysis of patient data focusing on genotype, pacing parameters, and arrhythmic events.
  • Evaluation of the impact of bradycardia and pauses on repolarization in LQTS.

Main Results:

  • LQT3 genotype patients may particularly benefit from pacing due to worsened repolarization dispersion during bradycardia.
  • Pacing may be beneficial for LQTS patients experiencing pause-dependent arrhythmias.
  • Premature to exclude benefits of pacing in other LQTS genotypes.

Conclusions:

  • Optimized patient selection and pacemaker programming, including a fast lower rate limit and disabling pause-inducing features, can help prevent arrhythmic death in LQTS.
  • Pause-prevention pacing algorithms show promise for this patient population.
  • Further research is warranted to fully elucidate the role of pacing in all LQTS genotypes.

Related Concept Videos

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Dysrhythmias V: Evaluating Dysrhythmias01:30

Dysrhythmias V: Evaluating Dysrhythmias

Dysrhythmias, also known as arrhythmias, are disturbances in the heart's rhythm that range from benign to life-threatening. A thorough evaluation is crucial for appropriate management and involves a comprehensive medical history, physical examination, and various diagnostic tests.Medical HistorySymptoms: Collect detailed information on palpitations, dizziness, syncope, chest pain, and fatigue. Note their onset, frequency, and triggers.Previous Cardiac Issues: Document any history of heart...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Dysrhythmias IV: Characteristics of Bradyarrhythmias01:18

Dysrhythmias IV: Characteristics of Bradyarrhythmias

Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...